05. July 2018

In part I of this series, I wrote about the financial unsustainability of antibiotics development. Revenues and profits of the new therapies launched since 2010 do not match the costs of development and thus most large pharmaceutical companies and biotech investors have stopped supporting antibiotic development. Fixing the broken business system will require a concerted effort by all stakeholders: payers, physicians, regulators, and the biopharmaceutical industry on a global scale. In this part...

05. July 2018

Antimicrobial resistance and its resulting dire consequences have finally become well recognized. Still, the problem continues to proliferate, killing thousands each year. Bacteria are amazingly resilient and will over time develop resistance to whatever we throw their way trying to kill them. But this is only half of the underlying reason for the problem and the half that we can’t do anything about. The other half of the reason is that the economic model for anti-infective drug development...